The 29 references in paper С. Зырянов К., Ю. Белоусов Б., С. Зырянов К., Ю. Белоусов Б. (2013) “НОВЫЕ АНТИКОАГУЛЯНТЫ: ПОВЫШЕНИЕ ЭФФЕКТИВНОСТИ ИЛИ СНИЖЕНИЕ БЕЗОПАСНОСТИ?” / spz:neicon:aterotromboz:y:2013:i:1:p:38-43

1
Cohen A. T., Agnelli G., Anderson F. A., Arcelus J. I., Bergqvist D., Brecht J. G. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost
(check this in PDF content)
2
07; 98: 756–64. 2. Hirsh J., Raschke R. Heparin and low-molecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S–203S.
(check this in PDF content)
3
Hochman J. S., Wali A. U., Barvila D. et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999; 138: 313– 8.
(check this in PDF content)
4
Hirsh J., Warkentin T. E., Raschke R., Granger C., Ohman E. M., Dalen J. E. Heparin and low-molecular- weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S–510S.
(check this in PDF content)
5
Geerts W. H., Bergqvist D., Pineo G. F., Heit J. A., Samama C. M., Lassen M. R. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133 (6 suppl): S381–453.
(check this in PDF content)
6
www.grls.rosminzdrav.ru
(check this in PDF content)
7
Diuguid D. L. Choosing a Paranteral Anticoagulant Agent. N Engl J Med 2001; 345:18, 1340–1341.
(check this in PDF content)
8
Панченко Е. П. Антикоагулянтная терапия в кардиологии: вчера, сегодня завтра. Кардиология. – 2010. – No 7. – С. 4–7.
(check this in PDF content)
9
Eriksson B. I., Dahl O. E., Rosencher N., Kurth A. A., van Dijk C. N., Frostick S. P. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J ThrombHaemost 2007; 5: 2178–85.
(check this in PDF content)
10
Eriksson B. I., Dahl O. E., Huo M. H., Kurth A. A., Hantel S., Hermansson K. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721–9.
(check this in PDF content)
11
Lassen M. R., Ageno W., Borris L. C., Lieberman J. R., Rosencher N Bandel T. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–86.
(check this in PDF content)
12
Turpie A. G., Lassen M. R., Davidson B. L., Bauer K. A., Gent M., Kwong L. M. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673–80.
(check this in PDF content)
13
Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., Hornick P. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized doubleblind trial. Lancet 2010; 375: 807–15.
(check this in PDF content)
14
Lassen M. R., Gallus A., Raskob G. E., Pineo G., Chen D., Ramirez L. M. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487–98.
(check this in PDF content)
15
Gomez-Outes A., Terleira-Fernandez A. I., SuarezGea L., Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for tromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344: e3675.
(check this in PDF content)
16
Yoshida R. de A., Yoshida W. B., Maffei R. et al. Systematic review of randomized controlled trials of new anticoagulants for venous tromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin. Annals of Vascular Surgery 2013; 27 (3): 355–369.
(check this in PDF content)
17
Connolly S. J., Ezekowitz M. D., Yusuf S. et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17; 361 (12): 1139–51.
(check this in PDF content)
18
Uchino K., Hernandez A. V. Dabigatran Association with higher risk of acute coronary events. Metaanalysis of noninferiority randomized controlled trials. Arch Intern Med. Published online January 9, 2012. doi:10.1001/archinternmed. 2011. 1666.
(check this in PDF content)
19
Ezekowitz M. D., Reilly P. A., Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100 (9): 1419–1426.
(check this in PDF content)
20
Schulman S., Kearon C., Kakkar A. K. et al; RECOVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361 (24): 2342–2352.
(check this in PDF content)
21
Oldgren J., Budaj A., Granger C. B. et al. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32 (22): 2781–2789.
(check this in PDF content)
22
Eriksson B. I., Dahl O. E., Huo M. H. et al; RENOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105 (4): 721–729.
(check this in PDF content)
23
Eriksson B. I., Dahl O. E., Rosencher N. et al; RENOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370 (9591): 949–956.
(check this in PDF content)
24
Eriksson B. I., Dahl O. E., Rosencher N. et al; REMODEL Study Group. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5 (11): 2178–2185.
(check this in PDF content)
25
Albers G. W., Diener H. C., Frison L. et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005; 293 (6): 690–698.
(check this in PDF content)
26
Christersson C., Oldgren J., Wallentin L., Siegbahn A. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med. 2011; 270 (3): 215–223.
(check this in PDF content)
27
Connolly S. J., Eikelboom J., Joyner C. et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364 (9): 806–817.
(check this in PDF content)
28
Patel M. R., Mahaffey K. W., Garg J. et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365 (10): 883–891.
(check this in PDF content)
29
Granger C. B., Alexander J. H., McMurray J. J. et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981–992. Medline: 21870978. 2
(check this in PDF content)